MARKET

BRNS

BRNS

Barinthus Biotherapeutics plc
NASDAQ
0.6796
-0.0314
-4.42%
After Hours: 0.6864 +0.0068 +1.00% 18:36 05/15 EDT
OPEN
0.7300
PREV CLOSE
0.7110
HIGH
0.7300
LOW
0.6369
VOLUME
10.75K
TURNOVER
--
52 WEEK HIGH
2.920
52 WEEK LOW
0.5120
MARKET CAP
27.76M
P/E (TTM)
-0.5273
1D
5D
1M
3M
1Y
5Y
1D
Barinthus Biotherapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS
Barchart · 5d ago
Weekly Report: what happened at BRNS last week (0504-0508)?
Weekly Report · 5d ago
Weekly Report: what happened at BRNS last week (0427-0501)?
Weekly Report · 05/04 10:08
Barinthus Biotherapeutics GAAP EPS of -$0.14
Seeking Alpha · 05/01 12:51
Analyst Flags High Risk in Barinthus Biotherapeutics’ Forward-Looking Statements and Guidance Reliability
TipRanks · 05/01 06:00
Barinthus’ VTP-300 Hepatitis B Study Reaches Completion: What Investors Should Watch Next
TipRanks · 04/30 16:30
Barinthus Biotherapeutics Q1 EPS $(0.14) Beats $(0.30) Estimate
Benzinga · 04/30 11:59
Why Qualcomm Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Benzinga · 04/30 09:26
More
About BRNS
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.

Webull offers Barinthus Biotherapeutics PLC - ADR stock information, including NASDAQ: BRNS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BRNS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BRNS stock methods without spending real money on the virtual paper trading platform.